Furthermore, the expression level of SKP2 is negatively associated with the survival of cancer patients—including those with prostate cancer [29], breast cancer [30,31], or lung cancer [32]—suggesting that SKP2 acts as an oncogene. Here, SKP2 is linked to prostate cancer.